Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
Congenital mesoblastic nephroma was originally considered to be a benign neoplasm. A more aggressive cellular form, however, that has a close relationship to congenital fibrosarcoma, is widely described. Previous reported sites of metastases are the lungs, heart, brain, and bone. We describe a patient with isolated metastasis to liver and review the management, together with evidence that it may be more appropriate to use a vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) regimen rather than Wilm's tumor-based regimens in those cases for which chemotherapy is indicated.
Patel
Yatin
Y
Department of Paediatric Surgery, John Radcliffe Hospital, Headington, Oxford, United Kingdom.
Mitchell
Christopher D
CD
Hitchcock
Rowena J
RJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007223:Infant; D007680:Kidney Neoplasms / Q000151:congenital* / Q000188:drug therapy* / Q000473:pathology; D008113:Liver Neoplasms / Q000151:congenital / Q000188:drug therapy* / Q000378:metabolism*; D018201:Nephroma, Mesoblastic / Q000151:congenital / Q000188:drug therapy* / Q000556:secondary*; D012509:Sarcoma / Q000188:drug therapy*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D007069:Ifosfamide